Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2
| Autor: | Kuan Der Lee, Hsing Kun Liu, Chih G. Chen, Yan Chung Shih, Mei Lien Cheng, Hsin Wei Chen |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Interleukin 2
Antigens Differentiation T-Lymphocyte Cytotoxicity Immunologic Cancer Research CD3 Complex medicine.drug_class medicine.medical_treatment Recombinant Fusion Proteins T-Lymphocytes Biology Monoclonal antibody Lymphocyte Activation Mice Antigen medicine Tumor Cells Cultured Animals Mice Inbred C3H Anti-CD3 Antibody Interleukin Antibodies Monoclonal Receptors Interleukin-2 General Medicine Immunotherapy Neoplasms Experimental Flow Cytometry Fusion protein Virology Recombinant Proteins Cell biology Killer Cells Natural Oncology biology.protein Interleukin-2 Electrophoresis Polyacrylamide Gel Female Antibody medicine.drug |
| Zdroj: | Oncology reports. 15(5) |
| ISSN: | 1021-335X |
| Popis: | T cells can be activated in vitro by monoclonal antibodies to CD3 (anti-CD3) to become non-MHC restricted killer cells (CD3-AK). Anti-CD3 activation upregulates the expression of the interleukin (IL)-2 receptors on T cells whose expansion is facilitated by IL-2. The therapeutic effect of in vivo administration of anti-CD3 and IL-2 has been investigated in many types of human cancers. To circumvent the toxicities posed by systemic administration of high-dose IL-2, there is interest in forming a strategy for targeting and concentrating IL-2 at the site where it is needed. This study investigates the feasibility of constructing a novel fusion protein consisting of IL-2 fused to the constant region of anti-CD3 antibody. Our results indicate that the specific IL-2 receptor-binding capability and bioactivity of the IL-2 portion as well as the CD3-binding and biological functions of anti-CD3 portion remain intact in this anti-CD3/IL-2 fusion protein. Thus, cytokines fused to anti-CD3 antibody by genetic engineering is feasible and may provide a new class of immunotherapeutics for cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|